Bibliography
- World Health Organization. International agency for research on cancer. GLOBOCAN. 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx
- El-Serag HB. Hepatocellular Carcinoma. N Engl J Med 2011;365:1118-12
- Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55
- Sawada Y, Ofuji K, Sakai M, et al. Immunotherapy for hepatocellular carcinoma: Current status and future perspectives[M]. INTECH Open Access Publisher, Rijeka,Croatia; 2013
- Romani L, Bistoni F, Gaziano R, et al. Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood 2004;103(11):4232-9
- Romani L, Bistoni F, Perruccio K, et al. Thymosin alpha1 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance. Blood 2006;108(7):2265-74
- Romani L, Bistoni F, Montagnoli C, et al. Thymsoin alpha 1: an endogenous regulator of inflammation, immunity, and tolerance. Ann N Y Acad Sci 2007;1112:326-38
- Romani L, Moretti S, Fallarino F, et al. Jack of all trades: thymosin alpha 1 and its pleiotropy. Ann N Y Acad Sci 2012;1269:1-6
- Giuliani C, Napolitano G, Mastino A, et al. Thymosin-alpha1 regulates MHC class I expression in FRTL-5 cells at transcriptional level. Eur J Immunol 2000;30(3):778-86
- SinibaldiVallebona P, Pierimarchi P, Moroni G, et al. Thymalfasin up-regulates tumor antigen expression in colorectal cancer cells. XXXth Meet Int Soc Oncodevel Biol Med 2002
- Garaci E, Pica F, Serafino A, et al. Thymosin alpha 1 and cancer: action on immune effector and tumor target cells. Ann N Y Acad Sci 2012;1269:11-18
- Stefanini GF, Foschi FG, Castelli E, et al. Alpha-1-thymosin and transcatheter arterial chemoembolization in hepatocellular carcinoma patients: a preliminary experience. Hepatogastroenterology 1998;45:209-15
- Zhang WJ. Transcatheter arterial chemotherapy and embolization plus thymosin alpha 1 for treatment of hepatocellular carcinoma. J Gastroenterol Hepatol 2004;15:A401
- Li ZS. HCC patients treated with TACE combined with thymalfasin: one year follow up. Paper presented at: Shanghai International Oncology Conference; 2001
- Cheng S, Wu M, Chen H, et al. Combination transcatheter hepatic arterial chemoembolization with thymosin alpha 1 on recurrence prevention of hepatocellular carcinoma. Hepatogastroenterology 2004;51:1445-7
- Cheng S, Wu M, Chen H, et al. Transcatheter hepatic arterial chemoembolization and thymosin in postoperative treatment of hepatocellular carcinoma. Chinese J Oncol 2004;26(5):305-7
- Cheng S, Wu M, Chen H, et al. Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B. Chinese J Oncol 2005;27(2):114-16
- Cheng S, Ding G, Shi J, et al. Role of antivirus therapy in treatment of hepatocellular carcinoma with chronic hepatitis B infection. Chinese-Ger J Clin Oncol 2005;4(6):330-3
- Cheng S, Wu M, Chen H, et al. Antiviral therapy using lamivudine and thymosin alpha 1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006;53:249-52
- Gish RG, Gordon SC, Nelson D, et al. A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma. Hepatol Int 2009;3(3):480-9
- Gu X, Jiang Z, Yang M. Efficacy of sorafenib with thymosin α1 for patients with advanced hepatocellular carcinoma [J]. Jiangsu Med J 2010;21:004